KUALA LUMPUR, June 6 (Bernama) -- Tessa Therapeutics Ltd (Tessa) has announced two presentations featuring clinical data from its autologous CD30.CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy (TT11X) will be featured at the 17th International Conference on Malignant Lymphoma (ICML) from June 13-17, at Lugano, Switzerland.
TT11 is currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients. A poster providing first peak into data from this combination study will be presented at ICML 2023.
Meanwhile, TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on the company’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
According to Tessa in a statement, an abstract highlighting updated data from the ongoing Phase 1 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ICML 2023.
A clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumours, Tessa has its global headquarters in Singapore, where it has built a state-of-the-art, commercial cell therapy manufacturing facility.
-- BERNAMA
No comments:
Post a Comment